

# Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App

NCT06675643

---

**Status** RECRUITING  
**Sponsor** Mayo Clinic  
**Enrollment** 100 participants

## Plain Language Summary

---

This study is testing a smartphone app called Vigilant that remotely monitors patients receiving dual immunotherapy (ipilimumab and nivolumab) for skin cancer or melanoma. The goal is to detect side effects earlier so they can be managed before they become serious.

**\*\*You may be eligible if...\*\***

- You have skin cancer or melanoma and are starting treatment with the combination of ipilimumab and nivolumab (dual immune checkpoint inhibitor therapy)

**\*\*You may NOT be eligible if...\*\***

- You do not meet the above inclusion criteria

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (1)

- Any skin cancer/melanoma patient starting dual [ipilimumab/nivolumab (IPI/NIVO)] immune checkpoint inhibitor (ICI) therapy

## Locations (1 total)

---

Mayo Clinic in Rochester, Rochester, Minnesota, United States